OncoMatch/Clinical Trials/NCT05975749

Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer

Is NCT05975749 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Serplulimab and Trastuzuma for gastric cancer.

Phase 2RecruitingFudan UniversityNCT05975749Data as of May 2026

Treatment: Serplulimab · Trastuzuma · Chemotherapy — The purpose of this study is to find out whether treatment with Serplulimab combined with Trastuzumab and Chemotherapy will improve the survival of gastric cancer patients with stage II-III after surgery.

Check if I qualify

Extracted eligibility criteria

Cancer type

Gastric Cancer

Biomarker criteria

Required: HER2 (ERBB2) overexpression

Her2+ diagnosed by Immunohistochemistry

Required: HER2 (ERBB2) amplification

Her2+ diagnosed by FISH

Disease stage

Required: Stage II, III

Excluded: Stage I, IV

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: chemotherapy

Cannot have received: radiation therapy

Cannot have received: immunotherapy

Cannot have received: targeted therapy

Lab requirements

Blood counts

WBC≥3.5 x 10^9 /L, NEU≥1.2 x 10^9 /L, PLT≥90 x 10^9 /L and HGB≥80g/L

Kidney function

normal kidney function

Liver function

normal liver function

Cardiac function

normal electrocardiogram

normal peripheral blood routine, liver and kidney function and electrocardiogram （WBC≥3.5 x 10^9 /L, NEU≥1.2 x 10^9 /L,PLT≥90 x 10^9 /L and HGB≥80g/L)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify